Resources

Your selections:

Clear all

Show Filters

We found 252 resources that match your search.

The following side effects have been associated with the use of raltegravir:

Document Date:

Document Date:

Required documentation of risk/benefit category and approval of clinical studies for inclusion of children by institutional review boards/ethics committees based on 45 CFR 46, Subpart D.

Document Date:

Document Date:

Ribasphere is a nucleoside analogue indicated for the treatment of chronic hepatitis C (CHC) virus infection in combination with peginterferon alfa-2a in patients 5 years of age and older with compensated liver disease not previously treated with interferon alpha, and in adult CHC patients…

Document Date:

Ribavirin is a nucleoside analogue indicated for the treatment of chronic hepatitis C (CHC) virus infection in combination with peginterferon alfa-2a in patients 5 years of age and older with compensated liver disease not previously treated with interferon alpha, and in adult CHC patients…

Document Date:

Document Date:

Document Date:

Document Date:

Rifampin is indicated in the treatment of all forms of tuberculosis.

Document Date:

Document Date:

The following side effects have been associated with the use of rifapentine:

Document Date:

The following serious side effects have been associated with the use of rilpivirine: Depression or mood changes. Be sure to contact your health care provider immediately if you are feeling sad or hopeless, feeling anxious or restless, or have thoughts of hurting yourself (suicide) or have tried to…

Document Date:

NORVIR is an HIV protease inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

Document Date:

Document Date:

Document Date:

Document Date:

Document Date:

Document Date:

.zip file contains: Case review on adverse events Safety training presentations on adverse events, expedited reporting and assessment, Expedited reporting via DAERS a safety training case study handout Training given in the Republic of South Africa in October 2016.

Document Date:

Document Date: